Insulet (PODD) Investor presentation summary

Financial performance

• Revenue rose from $1.1B in 2021 to $2.7B in 2025, a 25% CAGR; adjusted operating margin reached 17.6% in 2025, up from 9.5% in 2021.

• Adjusted EPS increased from $0.86 in 2021 to $4.97 in 2025, a 55% CAGR; free cash flow reached $378M in 2025, up from negative $180M in 2021.

Market position and opportunity

• Omnipod sales drove 66% of AID market growth from 2020–25; sales CAGR was 26% versus 8% for other companies, with nearly 50% of global AID revenue share.

• Addressable market today exceeds $30B across ~8M people with diabetes; the AID market is ~$6B, with a line of sight to ~$9B by 2028.

• The U.S. system is the most requested and prescribed AID system and leads new customer starts; the international business leads European new-to-pump users and accounts for ~30% of revenue.

Product development

• 2026 Omnipod 5 plans include a 100 mg/dL glucose target, algorithm improvements, integration with all major CGM sensors, and Omnipod Discover for HCP insights and care optimization.

• Omnipod 6 is designed for a 2027 launch, with clinical results and a 510(k) filing planned for 2026; proposed features include an improved algorithm, over-the-air configuration, and better connectivity.

• Fully closed-loop AID for T2D is planned for a 2028 launch, following a pivotal study start in 2026 and 510(k) filing in 2027; the design aims to require no meal announcements and support self-start.